BioAffinity Technologies, Financials
BIAF Stock | USD 0.28 0.01 2.62% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.0 | 1.59 |
|
|
Investors should never underestimate BioAffinity Technologies,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BioAffinity Technologies,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in bioAffinity Technologies,.
Net Income |
|
BioAffinity | Select Account or Indicator |
Understanding current and past BioAffinity Technologies, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioAffinity Technologies,'s financial statements are interrelated, with each one affecting the others. For example, an increase in BioAffinity Technologies,'s assets may result in an increase in income on the income statement.
BioAffinity Technologies, Stock Summary
BioAffinity Technologies, competes with Intelligent Bio, and Precipio. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
CUSIP | 09076W109 |
Location | Texas; U.S.A |
Business Address | 22211 West Interstate |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.bioaffinitytech.com |
Phone | 210 698 5334 |
Currency | USD - US Dollar |
BioAffinity Technologies, Key Financial Ratios
Return On Equity | -1.52 | ||||
Profit Margin | (1.19) % | ||||
Operating Margin | (0.87) % | ||||
Price To Sales | 0.55 X | ||||
Revenue | 2.53 M |
BioAffinity Technologies, Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 145.6K | 1.5M | 12.2M | 8.2M | 9.5M | 5.0M | |
Other Current Liab | 976.1K | 1.6M | 541.9K | 1.1M | 1.3M | 1.1M | |
Net Debt | 9.9M | 10.0M | (11.2M) | (1.2M) | (1.1M) | (1.1M) | |
Retained Earnings | (22.2M) | (28.5M) | (36.7M) | (44.6M) | (40.1M) | (42.2M) | |
Accounts Payable | 191.4K | 230.4K | 345.0K | 604.8K | 695.5K | 730.3K | |
Cash | 83.1K | 1.4M | 11.4M | 2.8M | 3.2M | 3.6M | |
Other Current Assets | 34.0K | 76.1K | 531.9K | 321.0K | 369.2K | 220.1K | |
Total Liab | 15.2M | 17.2M | 1.1M | 3.4M | 3.0M | 2.9M | |
Total Current Assets | 118.7K | 1.4M | 12.0M | 4.0M | 4.6M | 4.0M | |
Short Term Debt | 10.0M | 11.2M | 251.7K | 460.2K | 414.2K | 393.4K |
BioAffinity Technologies, Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 382.2K | 1.0M | 2.5M | 37.1K | 42.7K | 40.6K | |
Gross Profit | (22.2K) | (4.8K) | 4.3K | 791.6K | 910.4K | 955.9K | |
Operating Income | (2.6M) | (2.2M) | (4.0M) | (8.0M) | (7.2M) | (6.8M) | |
Ebit | (6.9M) | (2.2M) | (5.6M) | (7.9M) | (7.1M) | (7.4M) | |
Research Development | 1.6M | 1.3M | 1.3M | 1.7M | 1.6M | 1.2M | |
Ebitda | (6.9M) | (2.2M) | (5.6M) | (7.6M) | (6.9M) | (7.2M) | |
Cost Of Revenue | 22.2K | 4.8K | 467.0 | 1.7M | 2.0M | 2.1M | |
Income Before Tax | (7.3M) | (6.3M) | (8.2M) | (7.9M) | (7.1M) | (7.5M) | |
Net Income | (7.3M) | (6.3M) | (8.2M) | (7.9M) | (7.1M) | (7.5M) | |
Income Tax Expense | 2.8K | 2.0K | 2.5K | 21.0K | 24.1K | 25.3K |
BioAffinity Technologies, Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | (495.4K) | 1.3M | 10.1M | (8.6M) | (7.7M) | (7.3M) | |
Free Cash Flow | (2.2M) | (2.0M) | (4.3M) | (6.1M) | (5.5M) | (5.7M) | |
Depreciation | 22.2K | 4.8K | 10.2K | 249.6K | 287.0K | 301.4K | |
Other Non Cash Items | 4.3M | (244.4K) | 3.7M | 964.1K | 1.1M | 2.0M | |
Capital Expenditures | 2.9K | 0.0 | 220.0K | 22.9K | 26.3K | 25.0K | |
Net Income | (7.3M) | (6.3M) | (8.2M) | (7.9M) | (7.1M) | (7.5M) | |
End Period Cash Flow | 83.1K | 1.4M | 11.4M | 2.8M | 3.2M | 3.6M |
BioAffinity Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioAffinity Technologies,'s current stock value. Our valuation model uses many indicators to compare BioAffinity Technologies, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioAffinity Technologies, competition to find correlations between indicators driving BioAffinity Technologies,'s intrinsic value. More Info.bioAffinity Technologies, is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, BioAffinity Technologies,'s Return On Equity is most likely to slightly decrease in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value BioAffinity Technologies, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.bioAffinity Technologies, Systematic Risk
BioAffinity Technologies,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioAffinity Technologies, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on bioAffinity Technologies, correlated with the market. If Beta is less than 0 BioAffinity Technologies, generally moves in the opposite direction as compared to the market. If BioAffinity Technologies, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one bioAffinity Technologies, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioAffinity Technologies, is generally in the same direction as the market. If Beta > 1 BioAffinity Technologies, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in BioAffinity Technologies, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioAffinity Technologies,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BioAffinity Technologies, growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
BioAffinity Technologies, March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioAffinity Technologies, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of bioAffinity Technologies,. We use our internally-developed statistical techniques to arrive at the intrinsic value of bioAffinity Technologies, based on widely used predictive technical indicators. In general, we focus on analyzing BioAffinity Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioAffinity Technologies,'s daily price indicators and compare them against related drivers.
Information Ratio | (0.17) | |||
Maximum Drawdown | 38.76 | |||
Value At Risk | (16.67) | |||
Potential Upside | 13.46 |
Complementary Tools for BioAffinity Stock analysis
When running BioAffinity Technologies,'s price analysis, check to measure BioAffinity Technologies,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies, is operating at the current time. Most of BioAffinity Technologies,'s value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies,'s price. Additionally, you may evaluate how the addition of BioAffinity Technologies, to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |